Aegis Therapeutics, LLC

47 articles about Aegis Therapeutics, LLC

• Neurelis Announces Acquisition Of Aegis Therapeutics, A Leading Drug Delivery Technology Company

  12/3/2018

  Aegis' Intravail® drug delivery technology utilized in Neurelis' VALTOCO™ Nasal Spray, a novel investigational treatment for epilepsy patients   [03-December-2018]   SAN DIEGO , Dec. 3, 2018 /PRNewswire/ -- Neurelis, Inc. today announced the acquisition of Aegis Therapeutics, a San Diego -based drug delivery technology company.  Aegis Therapeutics' proprietary portfol

• Aegis Therapeutics, LLC Announces Breakthrough In Non-Invasive, Rapid Onset, Acute Pain Control

  10/10/2017

• Opiant Pharma Licenses Aegis Therapeutics, LLC’ Intravail Drug Delivery Technology

  6/28/2017

• Aegis Therapeutics, LLC Awarded Russian Patent For Non-Invasive Delivery Of Triptan Anti-Migraine Drugs

  9/1/2015

• Aegis Therapeutics, LLC Awarded Third Patent For Metered Nasal Spray Parathyroid Hormone (PTH) Peptide Drug Formulations

  8/27/2015

• Aegis Therapeutics, LLC Awarded Chinese And Japanese Patents For Non-Invasive Delivery Of Triptan Anti-Migraine Drugs

  8/11/2015

• Dauntless Pharmaceuticals And Aegis Therapeutics, LLC Announce Licensing Agreement

  7/21/2015

• Aegis Therapeutics, LLC Awarded U.S. Patent No. 8,927,497 For Non-Invasive Delivery Of Anti-Seizure Drugs

  2/18/2015

• Aegis Therapeutics, LLC Awarded Patent For Intranasal Administration Of Active Agents To The Central Nervous System

  11/12/2014

• Aegis Therapeutics, LLC Awarded 2nd Patent For Monoclonal Antibody Formulations That Avoid Oxidative Damage Due To Polysorbate Surfactants

  10/7/2014

• Aegis Therapeutics, LLC Release: First Non-Injectable GLP-1 Analog For Type-2 Diabetes

  8/6/2014

• Aegis Therapeutics, LLC Awarded US Patent For Stable "Shirt-Pocket" Insulin Suitable For Metered Nasal Spray Or Injection

  7/8/2014

• Aegis Therapeutics, LLC Intravail® Technology Enhances Oral Bioavailability Of Tableted OTC Drugs

  3/13/2014

• Aegis Therapeutics, LLC Awarded Its First Patent For Oral Delivery Of Nucleotide-Based Drugs With High Bioavailability

  2/5/2014

• Aegis Therapeutics, LLC Celebrates 10th Anniversary

  10/28/2013

• Aegis Therapeutics, LLC Awarded Its First Patent for Non-Invasive Delivery of a Protein Drug to the Central Nervous System (CNS)

  10/9/2013

• Aegis Therapeutics, LLC Awarded 3rd Patent for Fast Acting Migraine Nasal Spray Treatment

  8/13/2013

• Aegis Therapeutics, LLC Awarded 2nd Patent for Fast Acting Migraine Nasal Spray Treatment

  5/14/2013

• Aegis Therapeutics, LLC Release: Biosuperior Formulations Reduce Industry Concerns About Biosimilar Pricing, Development Costs, and Patient Acceptance

  4/2/2013

• Aegis Therapeutics, LLC Awarded Patent for Absorption-Enhancing Self-Assembling Thixotropic Aqueous Hydrogels

  12/12/2012